evaluating the effects of clinical characteristics and therapeutic regimens on mortality in hospitalized patients with severe covid-19

Background: the coronavirus disease 2019 (covid-19) is highly contagious and has turned into a global health problem. in this study, we investigated the role of clinical and laboratory characteristics along with administered therapeutic agents in patients with covid-19, and identified some effective factors on the mortality of these individuals.methods: in this retrospective study, we evaluated the data from all the hospitalized patients who had been diagnosed with covid-19 between february 23 and may 23, 2020. the data were obtained from medical records. additionally, a checklist was used to record demographic, clinical, laboratory, imaging, and treatment data for each patient.results: totally, 478 patients were involved in this study, and their median age was 58.5 years. of these, 53.3% patients were male. the most common pre-existing underlying disease was hypertension (37.9%), and the mortality group had significantly more comorbidities (85.4%). higher neutrophil lymphocyte ratio (nlr), lymphopenia, and reduced hemoglobin were more frequent in the mortality group (p < 0.001). similarly, the need to be admitted to the intensive care unit was significantly greater in the mortality group (p<0.001). the most frequently administered therapeutic regimens included hydroxychloroquine and lopinavir/ritonavir, which did not have any correlation with survival outcome.conclusion: older age, opioid addiction, cardiovascular disease, kidney disease, baseline nlr and hemoglobin, and icu admission were independently associated with covid-19 mortality. on the other hand, hydroxychloroquine and lopinavir/ritonavir indicated no beneficial effects on patients’ outcome